1127 related articles for article (PubMed ID: 24164718)
1. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
Pathak V; Vasu S; Flatt PR; Irwin N
Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
[TBL] [Abstract][Full Text] [Related]
2. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
3. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
Yabe D; Seino Y
Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
[TBL] [Abstract][Full Text] [Related]
4. Novel extrapancreatic effects of incretin.
Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
[TBL] [Abstract][Full Text] [Related]
5. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
6. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
7. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2012 Apr; 97(4):1363-70. PubMed ID: 22319034
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves.
Mayer F; Gunawan AL; Tso P; Aponte GW
Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G23-G35. PubMed ID: 32421358
[TBL] [Abstract][Full Text] [Related]
9. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
[TBL] [Abstract][Full Text] [Related]
10. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
[TBL] [Abstract][Full Text] [Related]
12. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
13. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
Pacini G; Thomaseth K; Ahrén B
Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
[TBL] [Abstract][Full Text] [Related]
14. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives.
Ahrén B
Diabetes Metab; 2013 May; 39(3):195-201. PubMed ID: 23643349
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of circulating GIP and GLP-1 concentrations.
Almgren P; Lindqvist A; Krus U; Hakaste L; Ottosson-Laakso E; Asplund O; Sonestedt E; Prasad RB; Laurila E; Orho-Melander M; Melander O; Tuomi T; Holst JJ; Nilsson PM; Wierup N; Groop L; Ahlqvist E
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093273
[TBL] [Abstract][Full Text] [Related]
17. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes.
Ma J; Pilichiewicz AN; Feinle-Bisset C; Wishart JM; Jones KL; Horowitz M; Rayner CK
Diabet Med; 2012 May; 29(5):604-8. PubMed ID: 22004512
[TBL] [Abstract][Full Text] [Related]
18. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
[TBL] [Abstract][Full Text] [Related]
19. Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes.
Astiarraga B; Chueire VB; Souza AL; Pereira-Moreira R; Monte Alegre S; Natali A; Tura A; Mari A; Ferrannini E; Muscelli E
Diabetologia; 2018 Aug; 61(8):1829-1837. PubMed ID: 29732475
[TBL] [Abstract][Full Text] [Related]
20. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
